Pharmaceuticals in Mexico
Pharmaceuticals in Mexico industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Essential resource for top-line data and analysis covering the Mexico pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Mexican pharmaceuticals market had total revenues of USD 20.3bn in 2017, representing a compound annual growth rate (CAGR) of 5.8% between 2013 and 2017.
- In line with many developing nations, Mexico has been experiencing an epidemiological transition from communicable diseases to chronic degenerative diseases. It is these factors which are generating growth.
- A growing middle class and better access to health care services are greatly increasing consumer demand for pharmaceutical products in Mexico.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Mexico
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Mexico
- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Mexico pharmaceuticals market with five year forecasts
Reasons to buy
- What was the size of the Mexico pharmaceuticals market by value in 2017?
- What will be the size of the Mexico pharmaceuticals market in 2022?
- What factors are affecting the strength of competition in the Mexico pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Mexico's pharmaceuticals market?
Table of Contents
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market Segmentation 10
Geography segmentation 10
Market share 11
Market Outlook 12
Market value forecast 12
Five Forces Analysis 13
Buyer power 15
Supplier power 17
New entrants 19
Threat of substitutes 21
Degree of rivalry 22
Leading Companies 24
Bayer AG 24
Merck & Co., Inc. 28
Novartis AG 31
Pfizer Inc. 34
Macroeconomic Indicators 38
Country data 38
Industry associations 41
Related MarketLine research 41
About MarketLine 42
List of Figures
Figure 1: Mexico pharmaceuticals market value: USD billion, 2013-17
Figure 2: Mexico pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 3: Mexico pharmaceuticals market share: % share, by value, 2017
Figure 4: Mexico pharmaceuticals market value forecast: USD billion, 2017-22
Figure 5: Forces driving competition in the pharmaceuticals market in Mexico, 2017
Figure 6: Drivers of buyer power in the pharmaceuticals market in Mexico, 2017
Figure 7: Drivers of supplier power in the pharmaceuticals market in Mexico, 2017
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2017
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2017
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2017
Figure 11: Bayer AG: revenues & profitability
Figure 12: Bayer AG: assets & liabilities
Figure 13: Merck & Co., Inc.: revenues & profitability
Figure 14: Merck & Co., Inc.: assets & liabilities
Figure 15: Novartis AG: revenues & profitability
Figure 16: Novartis AG: assets & liabilities
Figure 17: Pfizer Inc.: revenues & profitability
Figure 18: Pfizer Inc.: assets & liabilities
List of Tables
Table 1: Mexico pharmaceuticals market value: USD billion, 2013-17
Table 2: Mexico pharmaceuticals market geography segmentation: USD billion, 2017
Table 3: Mexico pharmaceuticals market share: % share, by value, 2017
Table 4: Mexico pharmaceuticals market value forecast: USD billion, 2017-22
Table 5: Bayer AG: key facts
Table 6: Bayer AG: key financials (USD )
Table 7: Bayer AG: key financials (EUR)
Table 8: Bayer AG: key financial ratios
Table 9: Merck & Co., Inc.: key facts
Table 10: Merck & Co., Inc.: key financials (USD )
Table 11: Merck & Co., Inc.: key financial ratios
Table 12: Novartis AG: key facts
Table 13: Novartis AG: key financials (USD )
Table 14: Novartis AG: key financial ratios
Table 15: Pfizer Inc.: key facts
Table 16: Pfizer Inc.: key financials (USD )
Table 17: Pfizer Inc.: key financial ratios
Table 18: Mexico size of population (million), 2013-17
Table 19: Mexico gdp (constant 2005 prices, USD billion), 2013-17
Table 20: Mexico gdp (current prices, USD billion), 2013-17
Table 21: Mexico inflation, 2013-17
Table 22: Mexico consumer price index (absolute), 2013-17
Table 23: Mexico exchange rate, 2013-17
Single User License:
Corporate User License:
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"